CEL-SCI (CVM) Announces IDMC Conclusions From Interim Review of Phase 3 Head and Neck Cancer Trial Data
11/5/2013 10:00:54 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that a second interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine* (Leukocyte Interleukin, Injection) investigational new drug immunotherapy was conducted by an Independent Data Monitoring Committee (IDMC). The IDMC said that the data raised no safety concerns, and recommended that the Phase III study continue unmodified.
Help employers find you! Check out all the jobs and post your resume.
comments powered by